Table of Contents Author Guidelines Submit a Manuscript
Journal of Nucleic Acids
Volume 2010 (2010), Article ID 597098, 10 pages
http://dx.doi.org/10.4061/2010/597098
Research Article

Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines

1Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
2Department of Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA

Received 29 March 2010; Revised 14 July 2010; Accepted 1 September 2010

Academic Editor: Caroline Kisker

Copyright © 2010 Jun Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Davidson, L. Ma, M. Flagella, S. Geeganage, L. M. Gelbert, and C. A. Slapak, “An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines,” Cancer Research, vol. 64, no. 11, pp. 3761–3766, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Rosell, K. D. Danenberg, V. Alberola et al., “Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients,” Clinical Cancer Research, vol. 10, no. 4, pp. 1318–1325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. M. Bergman, P. P. Eijk, V. W. T. Ruiz van Haperen et al., “In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant,” Cancer Research, vol. 65, no. 20, pp. 9510–9516, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Bepler, I. Kusmartseva, S. Sharma et al., “RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4731–4737, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Nakahira, S. Nakamori, M. Tsujie et al., “Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer,” International Journal of Cancer, vol. 120, no. 6, pp. 1355–1363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Akita, Z. Zheng, Y. Takeda et al., “Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma,” Oncogene, vol. 28, no. 32, pp. 2903–2909, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Reynolds, C. Obasaju, M. J. Schell et al., “Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5808–5815, 2009. View at Publisher · View at Google Scholar
  8. G. Bepler, K. E. Sommers, A. Cantor et al., “Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 3, no. 10, pp. 1112–1118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Gautam, Z.-R. Li, and G. Bepler, “RRM1-induced metastasis suppression through PTEN-regulated pathways,” Oncogene, vol. 22, no. 14, pp. 2135–2142, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. T.-C. Chou, “Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies,” Pharmacological Reviews, vol. 58, no. 3, pp. 621–681, 2006. View at Publisher · View at Google Scholar
  11. M. Behn and M. Schuermann, “Sensitive detection of p53 gene mutations by a ‘mutant enriched’ PCR-SSCP technique,” Nucleic Acids Research, vol. 26, no. 5, pp. 1356–1358, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. T. D. Shanafelt, C. Loprinzi, R. Marks, P. Novotny, and J. Sloan, “Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1966–1974, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. G. V. Scagliotti, P. Parikh, J. Von Pawel et al., “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3543–3551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Simon, A. Sharma, X. Li et al., “Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2741–2746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Cobo, D. Isla, B. Massuti et al., “Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2747–2754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Ceppi, M. Volante, S. Novello et al., “ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine,” Annals of Oncology, vol. 17, no. 12, pp. 1818–1825, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler, “DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer,” New England Journal of Medicine, vol. 356, no. 8, pp. 800–808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Gautam and G. Bepler, “Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase,” Cancer Research, vol. 66, no. 13, pp. 6497–6502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Huang, S. Chubb, L. W. Hertel, G. B. Grindey, and W. Plunkett, “Action of 2',2'-difluorodeoxycytidine on DNA synthesis,” Cancer Research, vol. 51, no. 22, pp. 6110–6117, 1991. View at Google Scholar · View at Scopus